Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.12 USD | +1.14% | -0.94% | -27.71% |
Financials (USD)
Sales 2024 * | 126M | Sales 2025 * | 179M | Capitalization | 2.74B |
---|---|---|---|---|---|
Net income 2024 * | -313M | Net income 2025 * | -304M | EV / Sales 2024 * | 18.4 x |
Net cash position 2024 * | 426M | Net cash position 2025 * | 313M | EV / Sales 2025 * | 13.5 x |
P/E ratio 2024 * |
-8.1
x | P/E ratio 2025 * |
-8.64
x | Employees | 525 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
Latest transcript on Arrowhead Pharmaceuticals, Inc.
1 day | +1.14% | ||
1 week | -0.94% | ||
Current month | -22.66% | ||
1 month | -20.55% | ||
3 months | -32.46% | ||
6 months | -9.34% | ||
Current year | -27.71% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 07-11-30 | |
Director of Finance/CFO | 57 | 08-12-31 | |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglass Given
CHM | Chairman | 71 | 10-11-22 |
Michael Perry
BRD | Director/Board Member | 64 | 11-12-18 |
Adeoye Olukotun
BRD | Director/Board Member | 79 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.40% | 0 M€ | 0.00% | - | |
0.35% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 22.12 | +1.14% | 617,025 |
24-04-25 | 21.87 | -6.10% | 976,870 |
24-04-24 | 23.29 | -2.06% | 813,628 |
24-04-23 | 23.78 | -0.59% | 828,397 |
24-04-22 | 23.92 | +7.12% | 1,080,438 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.71% | 2.71B | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- ARWR Stock